Stem Cell Clinic

Meet the Founders of Cord Blood Registry – Video

01-02-2012 13:37 Meet founders of Cord Blood Registry, Tom and Wendy. Hear why they started CBR -- a family business dedicated to helping people live healthier lives through cord blood stem cell medicine. Today, CBR has grown, but the attention to healthy families is the same. For more than 15 years, Cord Blood Registry has led the umbilical cord banking industry in technical innovations and provided families with peace of mind and hope. CBR's experience and dedication to quality has enabled CBR to help more clients use their cord blood stem cells in treatments than any other family bank. Our research and development efforts are focused on helping leading clinical researchers advance stem cell regenerative medicine that may help families in the future. Ultimate use of cord blood stem cells will be determined by the treating physician who will consider if they are applicable for the condition and should come from the patient or a suitable donor (like an HLA matched sibling). There is no guarantee that treatments being studied in the laboratory or in clinical trials will be available in the future. CBR is the preferred choice of OB/Gyns. © 2011 Cord Blood Registry. All rights reserved. Privacy Policy.

Originally posted here:
Meet the Founders of Cord Blood Registry - Video

Stem Cell Therapy for Osteoarthritis and Sports Injuries: A Case Study – Video

08-02-2012 11:12 Stem Cell Treatment of Pro/Am dancer and orthodontist, Dr. Janet Vaughan. In attempt to get her dancing career back on track, Dr. Vaughan decided to undergo stem cell therapy at the Stem Cell Institute in Panama City, Panama. Dr. Jorge Paz, Medical Director at the Stem Cell Institute presents Dr. Vaughan's case discussing her injuries and subsequent recovery. After being unable to compete for 2 years, Dr. Vaughan is once again slated to compete on the professional dance circuit with her current professional partner, Mr. Eddie Stutts (Professional 10-Dance World Champion). From 2007-2009, Dr. Vaughan partnered with World Champion Tony Dovolani and competed extensively in the US, winning a National Reserve Pro/Am Rhythm title. Tony Dovolani is best known for his appearances on ABC's hit reality series, "Dancing with the Stars", and has teamed up with Chynna Phillips, Wendy Williams, Audrina Partridge, Kate Gosselin, Kathy Ireland, Susan Lucci, Jane Seymour and other celebrities on the show.

More here:
Stem Cell Therapy for Osteoarthritis and Sports Injuries: A Case Study - Video

(Captioned) Hearing Loss Research : CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss – Video

19-09-2011 13:52 Learn more at http://www.cordblood.com Learn how newborn stem cells are being researched as treatment for patients with hearing loss. An innovative study held at Children's Memorial Hermann Hospital in Houston will be evaluating the effects of a child's own cord blood as treatment for acquired hearing loss. Only CBR offers your family exclusive access to several groundbreaking clinical trials such as this one. CBR was chosen as the only bank to provide cord blood because these studies require consistent processing and storage methods to reduce any possible variables. To learn more about this study, please visit clinicaltrials.gov To learn more about the lifesaving potential of cord blood, order your free information kit here http://www.cordblood.com Disclaimer: Ultimate use of cord blood stem cells will be determined by the treating physician who will consider if they are applicable for the condition and should come from the patient or a suitable donor (like an HLA matched sibling). There is no guarantee that treatments being studied in the laboratory or in clinical trials will be available in the future. CBR is the preferred choice of OB/Gyns. Source: blind survey, GfK Market Measures, 04/07, funded by CBR. © 2011 Cord Blood Registry. All rights reserved. Privacy Policy

Read this article:
(Captioned) Hearing Loss Research : CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss - Video

IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports …

NEW YORK--(BUSINESS WIRE)--

IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (PINKSHEETS: SVFC.PK); (“IntelliCell”) or the (“Company”), was invited to demonstrate its stromal vascular fraction technology at the recent Baseball Injuries Symposium at the Andrews Sports Medicine Institute in Alabama held and sponsored by USA Baseball. The course Chairman is Dr. James Andrews, and moderated by PT Kevin Wilk, and Dr. Jeff Dugas. One of the courses presented during the three day event was on stem cell technology presented by Dr. Joshua Hackel. Dr. Hackel presented the state of regenerative medicine technology in the role of treating sports injuries. The link is http://www.mediafire.com/?u7bfa662e3r1sdp.

Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, "We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year."

About IntelliCell BioSciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioSciences is exploring storing the stromal vascular fraction in cryo-storage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.

The rest is here:
IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports ...

American CryoStem Completes Cell Processing for Clinical Study

RED BANK, NJ--(Marketwire -02/07/12)- American CryoStem Corporation (OTCQB: CRYO.OB - News) announced today that it has completed providing stem cell processing services for Personal Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin care products.

The study involves researching the regenerative function of a conditioned medium obtained from each participant's adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing.

John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, "CRYO's patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility."

The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician's office and sent to CRYO's laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products.

"We are very excited to announce our service agreement and participation in this clinical study for Personal Cell Sciences. This contractual manufacturing agreement reinforces our capabilities to provide CRYO's exceptional clinical processing for relevant adult stem cell related products," said Anthony Dudzinski, COO of American CryoStem. "We look forward to our continued business relationship with PCS and expanding these services to other developers to speed their product's time to market."

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO.OB - News) markets clinical processing products and services for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. CRYO's clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

View original post here:
American CryoStem Completes Cell Processing for Clinical Study